Benzodiazepine utilization patterns in Alzheimer's disease patients

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 6, 2003, Pages 511-515

  Lagnaoui, Rajaa ^a   Moore, Nicholas ^a   Moride, Yola ^b,c   Miremont Salamé, Ghada ^a   Bégaud, Bernard ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Benzodiazepines; Dementia; Drug use; Pharmacoepidemiology

Indexed keywords

BENZODIAZEPINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TACRINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COMMUNITY CARE; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DISEASE SEVERITY; DRUG USE; FALLING; FEMALE; GENDER; HEALTH HAZARD; HIP FRACTURE; HUMAN; INSTITUTIONAL CARE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; NEUROTOXICITY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT;

EID: 0042914788     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.853     Document Type: Article

References (24)

1. Morgan K. Hypnotics in the elderly: what cause for concern? Drugs 1990; 40: 688-696.
2. Shorr RI, Robin DW. Rational use of benzodiazepines in the elderly. Drugs Aging 1994; 4: 9-20.
3. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis. J Am Geriatr Soc 1999; 47: 30-39.
4. Pierfitte C, Thicoïpe M, Macouillard G, et al. Benzodiazepines in hip fracture of the elderly: a case-control study. Br Med J 2001; 322: 704-708.
5. Hering RMC, Stricker BH, de Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures. Arch Intern Med 1995; 155: 1801-1807.
6. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316: 363-369.
7. Patten SB, Williams JV, Love EJ. Self-reported depressive symptoms following treatment with corticosteroids and sedative hypnotics. Int J Psychiatr Med 1996; 26: 15-24.
8. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324: 1691-1698.
9. Greenblatt DJ, Shader RI, Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol 1989; 29: 866-872.
10. Bowen JD, Larson EB. Drug-induced cognitive impairment. Defining the problem and finding solutions. Drugs Aging 1993; 3: 349-357.
11. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993; 328: 1398-1405.
12. Mayer-Oakes SA, Kelman G, Beers MH, et al. Benzodiazepine use in older, community-dwelling Southern Californians: prevalence and clinical correlates. Ann Pharmacother 1993; 27: 416-421.
13. Morgan K, Dallosso H, Ebrahim S, Arie T, Fentem PH. Prevalence, frequency, and duration of hypnotic drug use among the elderly living at home. Br Med J 1988; 296: 601-602.
14. Block RI, DeVoe M, Stanley B, Stanley M, Pomara N. Memory performance in individuals with primary degenerative dementia: its similarity to diazepam-induced impairments. Exper Aging Res 1985; 11: 151-155.
15. Clarfield AM. The reversible dementias: do they reverse? Ann Intern Med 1988; 109: 476-486.
16. Starr JM, Whalley LJ. Drug-induced dementia. Drug Saf 1994; 11: 310-317.
17. Lagnaoui R, Bégaud B, Moore N, et al. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol 2002; 55: 314-318.
18. Bégaud B, Haramburu F, Miremont G. Pharmacoepidemiology of tacrine in Alzheimer's disease. Methods Find Exp Clin Pharmacol 1996; 18(Suppl. B): 77-78.
19. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
20. EGRET. Revision 4. Reference Manual. Seattle: Statistics and Epidemiology Research Corporation and Cytel Software Corporation, 1993.
21. Dartigues JF, Gagnon M, Michel P, et al. The Paquid research program on the epidemiology of dementia. Methods and initial results. Rev Neurol 1991; 147: 225-230.
22. Semla TP, Cohen D, Freels S, et al. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease. Pharmacotherapy 1995; 15: 465-501.
23. Schmader KE, Hanlon JT, Fillenbaum GG, Huber M, Pieper C, Horner R. Medication use patterns among demented, cognitively impaired and cognitively intact community-dwelling elderly people. Age Aging 1998; 27: 493-501.
24. Fourrier A, Letenneur L, Dartigues JF, Decamps A, Bégaud B. Medication consumption by the elderly living at home and in institution on the basis of the paquid cohort: frequency of polymedication and psychotropic drug use. Rev Geriatr 1996; 21: 473-482.